Phylogenetic classification of human papillomavirus genotypes in high-grade cervical intraepithelial neoplasia in women from a densely populated Brazilian urban region
Keywords:
Human papillomavirus 11, Human papillomavirus 16, Human papillomavirus 18, Human papillomavirus 6, Genotype, Cervical intraepithelial neoplasia, Cancer, Polymerase chain reactionAbstract
CONTEXT AND OBJECTIVE: Differences in human papillomavirus (HPV) types may correlate with the biological potential and invasion risk of high-grade cervical intraepithelial neoplasia (CIN 2 and CIN 3). The objective of this study was to determine the relationship between different combinations of HPV types and CIN severity. DESIGN AND SETTING: Cross-sectional study, at Universidade Estadual de Campinas (Unicamp). METHODS: Cervical samples from 106 women treated due to CIN 2 (18) or CIN 3 (88) were examined for specific HPV genotypes using Roche Linear Array® (LA-HPV). The proportions of CIN 2 and CIN 3 in groups of women infected with the HPV phylogenetic groups A7 and A9 were compared. Three groups were formed: women with single infections; multiple infections; and the whole sample. RESULTS: Multiple infections were detected in 68 samples (64.7%). The most frequent high-risk genotypes detected (single/multiple) were HPV 16 (57.1%), HPV 58 (24.7%), HPV 33 (15.2%), HPV 52 (13.3%), HPV 31 (10.4%), HPV 51 (7.6%) and HPV 18 (6.6%). Women without infection with HPV species Alpha 9 were less likely to have CIN 3 than were their Alpha 9 HPV-infected counterparts. HPV 16 and/or HPV 18, with or without associations with other viral types, were more frequently found in women with CIN 3 than in those with CIN 2. CONCLUSIONS: The severity of high-grade CIN may be aggravated by the presence of HPV types included in the Alpha 9 phylogenetic classification and by infections including HPV 16 and 18, singly or in combination with other HPV genotypes.
Downloads
References
Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-9.
Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in hi- gh-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003;89(1): 101-5.
Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavi- rus types associated with cervical cancer. N Engl J Med. 2003;348(6):518-27.
Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine. 2006;24 Suppl 3:S3/S42-51.
Baak JP, Kruse AJ, Robboy SJ, Janssen EA, van Diermen B, Skaland I. Dynamic behavioural interpretation of cervical intraepithelial neoplasia with molecular biomarkers. J Clin Pathol. 2006;59(10):1017-28.
Syrjänen KJ, Syrjänen SM. Papillomavirus infections in human pathology. England: John Wiley & Sons Ltd; 2000.
Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ. HPV-mediated cervical carcinogene- sis: concepts and clinical implications. J Pathol. 2006;208(2):152-64.
Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121(3):621-32.
Zuna RE, Allen RA, Moore WE, Lu Y, Mattu R, Dunn ST. Distribution of HPV genotypes in 282 women with cervical lesions: evidence for three categories of intraepithelial lesions based on morphology and HPV type. Mod Pathol. 2007;20(2):167-74.
Zuna RE, Allen RA, Moore WE, Mattu R, Dunn ST. Comparison of human papillomavirus genotypes in high-grade squamous intraepithelial lesions and invasive cervical carcinoma: evidence or differences in biologic potential of precursor lesions. Mod Pathol. 2004;17(11):1314-22.
de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papilloma- viruses. Virology. 2004;324(1):17-27.
Liaw KL, Hildesheim A, Burk RD, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infec Dis. 2001;183(1):8-15.
Rousseau MC, Pereira JS, Prado JC, Villa LL, Rohan TE, Franco EL. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis. 2001;184(12):1508-17.
Weissenborn SJ, Funke AM, Hellmich M, et al. Oncogenic human papillomavirus DNA loa- ds in human immunodeficiency virus-positive women with high-grade cervical lesions are strongly elevated. J Clin Microbiol. 2003;41(6):2763-7.
Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer. 2007;7(1):11-22.
Trottier H, Mahmud S, Costa MC, et al. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev. 2006;15(7):1274-80.
Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ. Histological typing of fema- le genital tract tumors. (International histological classification of tumors). 2nd ed. Berlin: Springer-Verlag; 1994.
Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomavi- ruses. J Clin Microbiol. 2000;38(1):357-61.
Castle PE, Sadorra M, Garcia F, Holladay EB, Kornegay J. Pilot study of a commercialized human papillomavirus (HPV) genotyping assay: comparison of HPV risk group to cytology and histology. J Clin Microbiol. 2006;44(11):3915-7.
Gargiulo F, De Francesco MA, Schreiber C, et al. Prevalence and distribution of single and multiple HPV infections in cytologically abnormal cervical samples from Italian women. Virus Res. 2007;125(2):176-82.
Giuliani L, Coletti A, Syrjänen K, Favalli C, Ciotti M. Comparison of DNA sequencing and Roche Linear array in human papillomavirus (HPV) genotyping. Anticancer Res. 2006;26(5B):3939-41.
Woo YL, Damay I, Stanley M, Crawford R, Sterling J. The use of HPV Linear Array Assay for multiple HPV typing on archival frozen tissue and DNA specimens. J Virol Methods. 2007;142(1-2):226-30.
Coutlée F, Rouleau D, Petignat P, et al. Enhanced detection and typing of human papillo- mavirus (HPV) DNA in anogenital samples with PGMY primers and the Linear array HPV genotyping test. J Clin Microbiol. 2006;44(6):1998-2006.
Meijer CJ, Snijders PJ, Castle PE. Clinical utility of HPV genotyping. Gynecol Oncol. 2006;103(1):12-7.
Prétet JL, Jacquard AC, Carcopino X, et al. Human papillomavirus genotype distribution in high grade cervical lesions (CIN 2/3) in France: EDITH study. Int J Cancer. 2008;122(2):424-7.
Wheeler CM, Hunt WC, Schiffman M, Castle PE; Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study Group. Human pa- pillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J Infect Dis. 2006;194(9):1291-9.
Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367(9518):1247-55.
